anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Primary progressive aphasia (PPA) and primary progressive apraxia of speech (PPAOS) are neurodegenerative syndromes characterized by progressive decline in language or speech. There is a growing number of studies investigating speech-language interventions for PPA/PPAOS. An updated systematic evaluation of the treatment evidence is warranted to inform best clinical practice and guide future treatment research. We systematically reviewed the evidence for behavioral treatment for speech and language in this population. Reviewed articles were published in peer-reviewed journals through 31 May 2021. We evaluated level of evidence, reporting quality, and risk of bias using a modified version of the American Speech-Language Hearing Association (ASHA) Levels of Evidence, an appraisal point system, additional reporting quality and internal/external validity items, and, as appropriate, the Single Case Experimental Design Scale or the Physiotherapy Evidence Database - PsycBITE Rating Scale for Randomized and Non-Randomized Controlled Trials. Results were synthesized using quantitative summaries and narrative review. A total of 103 studies reported treatment outcomes for 626 individuals with PPA; no studies used the diagnostic label PPAOS. Most studies evaluated interventions for word retrieval. The highest-quality evidence was provided by 45 experimental and quasi-experimental studies (16 controlled group studies, 29 single-subject designs). All (k = 45/45) reported improvement on a primary outcome measure; most reported generalization (k = 34/43), maintenance (k = 34/39), or social validity (k = 17/19) of treatment for at least one participant. The available evidence supports speech-language intervention for persons with PPA; however, treatment for PPAOS awaits systematic investigation. Implications and limitations of the evidence and the review are discussed.
This is an open-label (a medical research study in which participants and researchers are told which treatments the participants are receiving, "unblinded"), multi-center (when more than 1 hospital or medical school team work on a medical research study), randomized (study medication assigned by chance), stepwise, bolus plus intravenous infusion, fixed-flexible (arbitrary dose titration \[slow increase in drug dosage, guided by participant's responses\]) study. The study consists of 3 periods: Observation period (from the time of obtaining consent to the start of study treatment), Treatment period, and Follow-up period (from 24 hours after the initiation of study treatment \[discontinuation\] to 30 days after the initiation of study treatment). The participants will be randomly assigned to 1 of the following 3 treatment groups: 2+0.005 group, 1+0.01 group and 2+0.01 group. The treatment period consists of treatment with bolus injection (over 1 minute) followed by intravenous infusion (over 24 hours: Period 1 \[fixed-dose period\] of 3 hours and Period 2 \[flexible-dose period\] of 21 hours).The study will be conducted stepwise and hence, initially participants will be randomly assigned to 1 of the following 2 groups: 1+0.01 group and 2+0.005 group. Participants will receive nesiritide at an initial dose of 0.005 or 0.01 microgram per kilogram per minute (mcg/kg/min), and the dose escalation of 0.005 mcg/kg/min per dose will be conducted every 3 hours up to maximum of 0.03 mcg/kg/min in Period 2. Safety data of at least 5 participants will be assessed for each group, and after confirming the safety of 2 groups, the participants will be assigned to third group of nesiritide 2 microgram per kilogram (mcg/kg) +0.01 mcg/kg/min. Then participants will be followed up to a maximum of 30 days after the initiation of study treatment, in follow-up period. Participants will primarily be evaluated for the effect of nesiritide on hemodynamic parameters such as pulmonary capillary wedge pressure (PCWP), or if it is unmeasurable then it will be complemented with pulmonary arterial diastolic pressure (PADP). Participants' safety will also be monitored throughout the study.
<P>PROBLEM TO BE SOLVED: To provide a new treating agent effective for rheumatoid arthritis.  <P>SOLUTION: This treating agent of the rheumatoid arthritis is provided by using a substance having inhibitory activity against the activity of a protein kinase of which expression is increased in the cells of an animal suffering from the rheumatoid arthritis as compared with that in the cells of the animal not suffering from the rheumatoid arthritis, as an active ingredient. The protein kinase is preferably 1 or ≥2 protein kinases selected from the group consisting of tyrosine kinase and serine/threonine kinases. "The protein kinase of which expression is increased in the cells of the animal suffering from the rheumatoid arthritis as compared with that of the cells of the animal not suffering from the rheumatoid arthritis" is preferably selected from the group consisting of HCK, MET and RON. As the active ingredient, concretely, an inhibitor of Src family, a neutralizing antibody against the protein kinase or an inhibitor of MET are exemplified.  <P>COPYRIGHT: (C)2010,JPO&INPIT
A method, apparatus, and/or system for patient wellness monitoring using a wrist-worn device is disclosed. The wrist-worn device may include a faceplate device and a wristband monitoring device. In one step, it may be determined that the faceplate device is detached from the wristband monitoring device. In response to the determination, the wristband monitoring device may operate on battery power. A sensor may be activated on the wristband monitoring device to collect vital sign information of a user. The vital sign information of the user may be wirelessly transmitted from the wristband monitoring device and received by the faceplate device. Upon determining that the faceplate device is attached to the wristband monitoring device, a battery on the wristband monitoring device may be charged.
Aberrant cell proliferation is a hallmark of cancer, including breast cancer. Here, we show that USP27X is required for cell proliferation and tumorigenesis in breast cancer. We identify a PIM2-USP27X regulator of MYC signaling axis whose activity is an important contributor to the tumor biology of breast cancer. PIM2 phosphorylates USP27X, and promotes its deubiquitylation activity for MYC, which promotes its protein stability and leads to increase HK2-mediated aerobic glycolysis in breast cancer. Moreover, the PIM2-USP27X-MYC axis is also validated in PIM2-knockout mice. Taken together, these findings show a PIM2-USP27X-MYC signaling axis as a new potential target for breast cancer treatment.
PURPOSE: To purify a mouse IgG1 for diagnosing diseases and pregnancy by culturing a mouse IgG1 producing cell in a bovine serum containing medium, removing bovine IgG by a protein A column, adding a buffer solution to the filtrate and passing the filtrate through the protein A column. CONSTITUTION: A mouse IgG1 producing cell is cultured in a medium containing a bovine serum component to give a supernatant liquid of serum culture, which is used as a solution to be treated. The solution to be treated is passed through a first protein A column, bovine IgG in the solution to be treated is selectively adsorbed and removed under conditions of a low salt concentration/neutral pH. The filtrate having passed through the column is mixed with a buffer solution having a high salt concentration and a high pH. Then the mixed solution is fed to a second protein A column which is equilibrated with a buffer solution having a high salt concentration and a high pH.  Mouse IgG1 in the mixed solution is selectively adsorbed and the adsorbed mouse IgG1 is eluted and recovered with an acidic solution to efficiently purify the objective mouse IgG1 useful for diagnosing diseases such as cancers and pregnancy.
This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the control study arm will not receive a 1-hour in-person communication training.
BACKGROUND: Obesity is a rapidly increasing health problem in China, causing massive economic and health losses annually. Many techniques have emerged to help people with obesity better adhere to intervention programs and achieve their weight loss goals, including food replacement and internet-delivered weight loss consultations. Most studies on weight loss interventions mainly focused on the change in body weight or BMI; however, body fat, especially visceral fat mass, is considered the main pathogenic factor in obesity. In China, more reliable evidence is required on this topic. Moreover, it is unclear whether an integrated weight loss program combining food replacement products, mobile app-based platforms, and daily body composition monitoring using a wireless scale is useful and practical in China.
OBJECTIVE: In this 2-arm, parallel-designed, randomized study, we explored the effectiveness and safety of the Metawell (Weijian Technologies Inc) weight loss program in China, which combines prepackaged biscuits, a wireless scale, and a mobile app.
METHODS: Participants in the intervention group were guided to use food replacement products and a scale for weight loss and monitoring, whereas participants in the control group received printed material with a sample diet and face-to-face education on weight loss at enrollment. The intervention lasted for 3 months, and follow-up visits were conducted at months 3 and 6 after enrollment. Dual-energy x-ray absorptiometry and quantitative computed tomography were used to assess body fat. A multilevel model for repeated measurements was used to compare differences between the 2 groups.
RESULTS: In total, 220 patients were randomly assigned to intervention (n=110) and control (n=110) groups. Participants in the intervention group had significantly greater decreases in BMI, total body fat, visceral adipose area, and subcutaneous adipose area (all P<.001) than those in the control group. However, the rate of change in lean mass was not significantly different between the 2 groups (P=.62). Further, 35 participants in the intervention group reported adverse events. Constipation was the most frequently reported adverse event (11/110), followed by dizziness (6/110), hypoglycemia (4/110), fatigue (3/110), and gastritis (3/35).
CONCLUSIONS: The Metawell program was effective for weight loss. After the intervention, participants in the intervention group lost more body weight and body fat while retaining muscle mass than those in the control group.
In controlled clinical trials, single doses of 25, 50, or 100 mg of IMITREX Tablets were effective for the acute treatment of migraine in adults. There is evidence that doses of 50 and 100 mg may provide a greater effect than 25 mg (see CLINICAL TRIALS). There is also evidence that doses of 100 mg do not provide a greater effect than 50 mg. Individuals may vary in response to doses of IMITREX Tablets. The choice of dose should therefore be made on an individual basis, weighing the possible benefit of a higher dose with the potential for a greater risk of adverse events.

If the headache returns or the patient has a partial response to the initial dose, the dose may be repeated after 2 hours, not to exceed a total daily dose of 200 mg. If a headache returns following an initial treatment with IMITREX Injection, additional single IMITREX Tablets (up to 100 mg/day) may be given with an interval of at least 2 hours between tablet doses. The safety of treating an average of more than 4 headaches in a 30-day period has not been established.

Because of the potential of MAO-A inhibitors to cause unpredictable elevations in the bioavailability of oral sumatriptan, their combined use is contraindicated (see CONTRAINDICATIONS).

Hepatic disease/functional impairment may also cause unpredictable elevations in the bioavailability of orally administered sumatriptan. Consequently, if treatment is deemed advisable in the presence of liver disease, the maximum single dose should in general not exceed 50 mg (see CLINICAL PHARMACOLOGY for the basis of this recommendation).
In the event of overdosage, VIBATIV should be discontinued and supportive care is advised with maintenance of glomerular filtration and careful monitoring of renal function. Following administration of a single dose of VIBATIV 7.5 mg/kg to subjects with end-stage renal disease, approximately 5.9% of the administered dose of telavancin was recovered in the dialysate following 4 hours of hemodialysis. However, no information is available on the use of hemodialysis to treat an overdosage [see Clinical Pharmacology (12.3)]. 

The clearance of telavancin by continuous venovenous hemofiltration (CVVH) was evaluated in an in vitro study [see Nonclinical Toxicology (13.2)]. Telavancin was cleared by CVVH and the clearance of telavancin increased with increasing ultrafiltration rate. However, the clearance of telavancin by CVVH has not been evaluated in a clinical study; thus, the clinical significance of this finding and use of CVVH to treat an overdosage is unknown.
PURPOSE:To obtain the sol which has excellent shieldability of UV rays of a UV-A region and yields the transparent thin film having a high refractive index by adding hydrogen peroxide to the dispersion of titanium hydroxide and cerium hydroxide to dissolve the titanium hydroxide and the cerium hydroxide, then heating the dispersion. CONSTITUTION:The sol or gel mixture composed of the titanium hydroxide and the cerium hydroxide or the coprecipitated gel or sol of both is first prepd. The gel or sol is preferably so prepd. that the ratio of the titanium oxide and cerium oxide therein attains at least 0.05 CeO2/TiO2 (by weight ratio) in the final product. The hydrogen peroxide is then added to this gel or sol to dissolve the titanium hydroxide and the cerium hydroxide, by which a uniform aq. soln. is prepd. The soln. is thereafter hydrolyzed by heating at >=60 deg.C. The desired composite sol. dispersed with the particles compounded with the titanium oxide and the cerium oxide is obtd. if the sol is formed in such a manner.
PROBLEM TO BE SOLVED: To provide a method for producing a protoplast of cassava or its closely related species that is transformed to regenerate a plant, and to obtain starch having increased amylopectin content. SOLUTION: This method for producing the protoplast comprises the production of a frail germ-forming callus from explants of the cassava or its closely related species and the isolation of the protoplast from the frail germ-forming callus. Also, the protoplast obtained from the method is provided. Further, the method for transforming the cassava and its closely related species and the transformed protoplast obtained from the method are provided. In addition, the method for regenerating a plant body from the protoplast and the plant body of the cassava or its closely related species obtained by the method are provided. The starch isolated from the tuber of such cassava plant body contains increased amylopectin content. The starch and the method for isolating the starch from the plant body form the parts of the present invention.
Hydroxyurea causes severe myelosuppression. Do not initiate treatment with XROMI in patients if bone marrow function is markedly depressed. Bone marrow suppression may occur, and leukopenia is generally its first and most common manifestation. Thrombocytopenia and anemia occur less often and are seldom seen without a preceding leukopenia.

Some patients, treated at the recommended initial dose of 15 mg/kg/day, have experienced severe or life-threatening myelosuppression.

Evaluate hematologic status (CBC, reticulocyte count) prior to and every 2 weeks during dose-escalation period of XROMI treatment. Once a stable dose of XROMI is achieved, monitor every 4 weeks. Provide supportive care and modify dose or discontinue XROMI as needed. Recovery from myelosuppression is usually rapid when therapy is interrupted. [see Dosage and Administration (2.1)].
In basic research and drug discovery there is a need to provide protein reagents with high activity. In particular proteins that are used in assays must have a good shelf life and a consistent activity. As a system of measuring actin polymerization, pyrene labeled actin was developed in 1983 by Kouyama and Mihashi. However, prior to this disclosure, pyrene actin has been impossible to store for longer than one month because the activity would be lost due to protein denaturation and frozen pyrene actin immediately lost activity. This disclosure relates a method for stabilizing pyrene labeled actin for extended storage times and an optimal storage buffer thus creating a reproducible source of pyrene actin for various assays. Using the processes described herein, pyrene actin has been stored for greater than 3 years at 4° C. which makes it a viable product for retail.
As a variant of Vaccinia virus, Buffalopox virus is known to cause Buffalopox disease. In recent times, sporadic outbreaks of the infection in humans have been reported, especially in the endemic countries of Southeast Asia. Though mortality has not been high, associated morbidity is significant. Due to waning cross-protective immunity against smallpox, Buffalopox virus is one of the several orthopox viruses likely to emerge or reemerge. To combat this virus, early recognition, isolation, and management of the infection in animals and humans is of prime importance. In addition, vaccination in animals and humans at risk of acquiring infection is essential as a means of limiting animal-to-animal and animal-to-human spread of the virus. With this in mind, a collaborative approach between the animal and human health sectors is indispensable.
PURPOSE: To obtain the subject formulation containing an avermectin compound, a hydrophobic carrier and a hydrogenated castor oil, exhibiting long-acting persistence, capable of being easily injected, and useful as a vermicide or antiparasitic agent. CONSTITUTION: This formulation comprises (A) an avermectin compound, (B) a hydrophobic carrier (e.g. glyceryl triacetate) and (C) a hydrogenated castor oil. The component A is preferably avermectin and ivertmectin which are represented by the formula (when the component A is the avermectin, the broken line is a double bond, and R1 does not exist, and when the component A is the ivermectin, the broken line is a single bond, R1 is H, and R2 is isopropyl, sec-butyl). The formulation is preferably prepared so that the component A is administered at a dose of 0.6-0.7mg/kg. The formulation is preferably subjected to a membrane sterilization treatment.
This research was planned in a quasi-experimental design with pretest-posttest control group. It is aimed to determine the effect of mandala technique on nausea-vomiting and comfort level in patients receiving ambulatory chemotherapy.

For this purpose, the research will be carried out with cancer patients receiving chemotherapy treatment on an outpatient basis at Gaziantep University Medical Faculty Training and Research Hospital and Gaziantep University Oncology Hospital between December 2022 and April 2023. The population of my research will consist of patients who receive outpatient chemotherapy treatment at Gaziantep University Faculty of Medicine Oncology Hospital. Individuals who meet the sampling selection criteria from the specified universe will constitute the sample of the research. Experimental research requires at least 20 samples. In order for a test to meet the parametric test conditions, references were made to the sources stating that the groups must have at least 30 individuals. In the research group of our study, it was planned to include 30 application and 30 control group patients. When these numbers are reached, it is planned to determine the sample impact power by performing power analysis, and to terminate the research when at least 80% preferably 100% positive impact power is reached. Randomization of the sample will be achieved by accepting the first patient who applied to the outpatient chemotherapy unit randomly and with an appointment at the beginning of the study to the control group, and the next patient to the experimental group. The patients will be included in the experimental and control groups in this order until the sample size is reached.

The implementation of the study will start after the necessary permissions are obtained, and the application group will be asked to paint the mandalas provided by the researcher for at least 30 minutes while they are in the chemotherapy unit. The patients will be given the necessary materials during their stay at home, they will be asked to paint mandalas at home for 4 days, and the patient will be supported by phone. No treatment other than standard care will be performed for the control group.
Women comprise a growing proportion of new HIV infections worldwide. Intravaginal rings (IVRs) used to deliver microbicides have the potential to significantly reduce the heterosexual transmission of HIV if found to be safe, acceptable, and effective against HIV infection. This study will investigate the safety and acceptability of a non-medicated silicone elastomer IVR in sexually active HIV uninfected women.

The expected duration of this study for each participant is 16 weeks. Study participants will be randomly assigned to one of two arms. Participants in Group A will insert an IVR into their vagina at study entry. The IVR will remain in place for 12 weeks until removed by a physician. Follow up will continue for an additional 4 weeks after IVR removal. Participants in Group B will not receive an IVR, but will follow the same study schedule as those in Group A.
NEW MATERIAL:A nitrogen-containing tetracyclic compound expressed by formula I [R1 and R2 are lower alkyl; R3 is H, lower alkyl, lower alkoxy or hydroxyl; (n) is integer 1-3]. EXAMPLE:5,10-Dihydro-2-hydroxy-1,3-dimethylindeno[1,2-b]indole. USE:Useful as an antiasthmatic agent, antiallergic agent (prevention and treatment of allergic dermatitis, allergic rhinitis, urticaria, etc.), anhtirheumatic agent, antithrombotic agent, remedy for arteriosclerosis, etc., and capable of exhibiting improved inhibitory action on lipoxygenase of a polyfunctional unsaturated fatty acid by oral addministration. PREPARATION:A phenylhydrazine compound expressed by formula II is reacted with a compound expressed by formula III (R4 is H, lower alkyl, etc.) to give a compound expressed by formula IV, which is then cyclized to afford a compound expressed by formula V. When R4 is lower alkyl, it is eliminated to give the aimed compound expressed by formula I.
Combination chemotherapy with Ifosfamide, Vincristine, Dactinomycin and Doxorubicin ("IVADo"). Second look and possible 3rd look surgery may be required. Radiation therapy is recommended only for residual disease after maximum surgery.